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Abstract
Type-1 (CB1) and type-2 (CB2) cannabinoid receptors belong to the rhodopsin family of G protein-coupled receptors, and are activated by
endogenous lipids termed ‘‘endocannabinoids’’. Recent reports have demonstrated that CB1R, unlike CB2R and other receptors and metabolic
enzymes of endocannabinoids, functions in the context of lipid rafts, i.e. plasma membrane microdomains which may be important in modu-
lating signal transduction. Here, we present novel data based on cell subfractionation, immunoprecipitation and confocal microscopy studies,
that show that in C6 cells CB1R co-localizes almost entirely with caveolin-1. We also show that trafficking of CB1R in response to the raft
disruptor methyl-b-cyclodextrin (MCD) is superimposable on that of caveolin-1, and that MCD treatment increases the accessibility of
CB1R to its specific antibodies. These findings may be relevant for the manifold CB1R-dependent activities of endocannabinoids, like the reg-
ulation of apoptosis and of neurodegenerative diseases.
 2007 Elsevier Ltd.
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Anandamide (AEA) and 2-arachidonoylglycerol (2-AG)
are the most prominent members of ‘‘endocannabinoids’’
(Bari et al., 2006a; Di Marzo, 2006). They bind to and activate
two inhibitory G protein-coupled receptors (GPCR), namely
type-1 (CB1R) and type-2 (CB2R) cannabinoid receptors
(Howlett, 2005). CB1R is localized mainly in the central
nervous system (Egertova et al., 2003), but also expressed in
peripheral tissues like immune cells (Klein et al., 2003). Con-
versely, CB2R is predominantly expressed peripherally, but it
is also present in the brain (Nunez et al., 2004; Van Sickle
et al., 2005). Activation of CB1 or CB2 receptors by AEA
or 2-AG has many central and peripheral effects (Bari et al.,
2006a; Di Marzo, 2006), obtained by triggering common
signaling pathways (Howlett, 2005; Di Marzo, 2006). It would
be of utmost importance to identify a possible differential
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these two receptor subtypes have been recognized as distinct
drug discovery targets for numerous potential therapeutic ap-
plications; these include food intake, cancer and immune sup-
pression (Bifulco and Di Marzo, 2002; Piomelli, 2003; Fowler,
2005). CB receptors, together with the enzymes that synthesize
(N-acyl-phosphatidylethanolamines-hydrolyzing phospholipase
D, NAPE-PLD) (Okamoto et al., 2004) or degrade (fatty
acid amide hydrolase, FAAH) (McKinney and Cravatt, 2005)
AEA, the enzymes that synthesize (diacylglycerol lipase,
DAGL) (Bisogno et al., 2003) or hydrolyze (monoacylglycerol
lipase, MAGL) (Dinh et al., 2002) 2-AG, and the AEA-binding
transient receptor potential channel vanilloid receptor subunit 1
(TRPV1), form the ‘‘endocannabinoid system’’ (Piomelli, 2003;
Bari et al., 2006a; Di Marzo, 2006).
Lipid rafts are subdomains of the plasma membrane that
contain high concentrations of cholesterol and glycosphingoli-
pids, and are well-known modulators of GPCR-dependent sig-
naling and membrane trafficking in central and peripheral cells
(Gajate and Mollinedo, 2005; Rodgers et al., 2005). Not sur-
prisingly, they had been proposed also as potential regulators
of CBR activity (Hinz et al., 2004; Barnett-Norris et al., 2005;
McFarland and Barker, 2005). Recently, we have shown that
treatment of rat C6 glioma cells for 30 min with the lipid rafts
disruptor methyl-b-cyclodextrin (MCD) doubles the binding ef-
ficiency (i.e., the maximum binding:affinity constant ratio) of
CB1R, and thus the CB1R-dependent actions of endocannabi-
noids; instead, MDC did not affect those activities mediated
by CB2R or TRPV1 (Bari et al., 2005). In addition, we found
that the activity of the endocannabinoid-metabolizing enzymes
NAPE-PLD, FAAH, DAGL and MAGL is not affected by
MCD, neither in central nor in peripheral cells (Bari et al.,
2006b). In this context, it should be recalled that caveolae are
a specialized subclass of lipid rafts, involved in cholesterol traf-
ficking within most cell types, endocytosis of external mole-
cules, and regulation of several signal transduction pathways
(Arcangeli and Becchetti, 2006). They have been proposed as
platforms for the accumulation of signaling molecules, and
may provide a physical location for the initiation of downstream
signaling events (Smythe et al., 2003). Caveolae have a charac-
teristic protein coat, a major component of which is caveolin
(Sotgia et al., 2006). To date three major caveolin isoforms
have been identified, and the most widespread of them, caveo-
lin-1 (CAV1), is expressed also in C6 cells (Silva et al., 1999).
In order to ascertain whether CB1R could reside within
caveolae, here we investigated the colocalization of CB1R
with CAV1 in C6 cells, by using subfractionation, immunopre-
cipitation and confocal microscopy techniques. We also inves-
tigated the trafficking of CB1R and CAV1 in response to MCD
treatment, in the light of its potential relevance for the regula-
tion of apoptosis and neurodegenerative diseases.
2. Materials and methods
2.1. Antibodies
Rabbit anti-CB1R polyclonal antibodies were from Affinity BioReagents,
Inc. (Golden, CO). Rabbit anti-CAV1, anti-TRPV1, and anti-CAV1 mousemonoclonal antibodies were from Santa Cruz Biotechnologies (Santa Cruz,
CA). Anti-NAPE-PLD rabbit polyclonal antibodies were from Cayman Chem-
ical (Ann Arbor, MI). Anti-FAAH polyclonal antibodies were elicited in rab-
bits against the conserved FAAH sequence VGYYETDNYTMPSPAMR
(Giang and Cravatt, 1997) conjugated to ovalbumin, and were prepared by
Primm S.r.l. (Milan, Italy). Anti-thyroid hormone receptor mouse monoclonal
antibody was from Calbiochem (La Jolla, CA). Goat anti-rabbit alkaline phos-
phatase conjugates (GAR-AP) were from Bio-Rad (Hercules, CA).
2.2. Cell culture and treatment
Rat C6 glioma cells were cultured in RPMI 1640 medium (Invitrogen Co.,
Carlsbad, CA), supplemented with 10% fetal bovine serum. Cells were main-
tained at 37 C in a humidified atmosphere with 5% CO2 and were fed every 2
days. Lipid raft disruption was performed by preincubating C6 cells for the in-
dicated periods of time at 37 C with 2.5 mM MCD (Sigma Chemical Co., St.
Louis, MO), followed by a washing step in phosphate-buffered saline (Bari
et al., 2005).
2.3. Purification of caveolae-enriched membrane fractions
Fractions enriched in caveolae were prepared by carbonate extraction fol-
lowed by gradient centrifugation (Song et al., 1996), adapted to C6 cells as re-
ported (Silva et al., 1999). Homogenates from C6 cells (300  106 cells/test)
were placed at the bottom of a discontinuous sucrose density gradient and
were spun in an SW41 Ti rotor (Beckman Instruments, Palo Alto, CA) at
188,000  g and 4 C for 22 h. Twelve 1 ml fractions were collected from
top to bottom, saving also the heavy pellet. Proteins from each fraction
were precipitated with 7.2% (v/v) trichloroacetic acid, and were solubilized
in SDSePAGE sample buffer (Xiang et al., 2002). The precipitated proteins
(50 mg/lane) were separated on 12% SDSePAGE gel, were electrotransferred
on 0.45 mm nitrocellulose filters (Bio-Rad), and then were subjected to
Western blot with rabbit anti-CAV1 (diluted 1:250) or rabbit anti-CB1R
(1:250) specific antibodies.
2.4. Immunoprecipitation
C6 cells (100  106/test) were sonicated in immunoprecipitation buffer
(10 mM TriseCl, pH 8, 150 mM NaCl, 2 mM phenylmethanesulfonyl fluoride,
60 mM octyl glucoside) and centrifuged at 4 C for 15 min at maximal speed
in a microcentrifuge, and extracts were prepared as reported (Rybin et al.,
2000). Immunoprecipitation was performed with the Protein G immuprecipi-
tation kit from Sigma Chemical Co. (St. Louis, MO) according to the manu-
facturer’s instructions. Briefly, whole cell extracts (1 mg) were incubated
overnight at 4 C with monoclonal antibody anti-caveolin1 (5 mg) or with an
irrelevant monoclonal antibody anti-thyroid hormone receptor (5 mg), then im-
munocomplexes were incubated with 30 ml of protein G-Sepharose beads for
2 h at 4 C. Beads were washed three times with immunoprecipitation buffer,
then bound proteins were eluted with 100 ml of SDSePAGE sample buffer and
boiled for 5 min (Rybin et al., 2000). Cell lysate (20 mg), immunodeplete su-
pernatants (20 mg/lane) and immunoprecipitates (4 ml/lane, corresponding to
4% of the immunoprecipitate) were immunoblotted with rabbit polyclonal an-
tibodies against caveolin-1 (1:250), CB1R (1:250), NAPE-PLD (1:250),
FAAH (1:250) and TRPV1 (1:250).
2.5. Confocal microscopy
C6 cells were settled on a glass coverslip at a density of 2  104 cells/cm2.
After 24 h C6 cells were treated with 2.5 mM methyl-b-cyclodextrin for the
indicated time or left untreated (control cells). Cells were then fixed for
10 min at room temperature with 4% paraformaldehyde and processed for
immunofluorescence (Terrinoni et al., 2004). Rabbit anti-CB1R antibodies
(diluted 1:100), and mouse anti-CAV1 antibodies (1:100) were made fluores-
cent by using the ‘‘Alexa Fluor 488 and 546 Monoclonal Antibody Labeling
Kit’’ (Molecular Probes, Eugene, OR). After immunofluorescence, coverslips
were mounted using Prolong Antifade Kit (Molecular Probes), and data were
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Florence, Italy) at an excitation of 488 nm (band of Ar laser) or 546 nm
(band of a HeNe laser).
3. Results
3.1. Colocalization of CB1R and CAV1
Membrane fractionation studies were carried out to access
the distribution of CB1R and CAV1 in C6 cells. CB1R was
found exclusively in membrane fractions enriched with
CAV1 (Fig. 1A), and its targeting to caveolae was further
Fig. 1. Localization of CB1R in C6 cells. (A) Western blot analysis of C6 cell
membranes (50 mg/lane) from gradient fractions stained for caveolin-1 (anti-
CAV1) or CB1 receptor (anti-CB1R). (B) Western blot analysis of C6 cell
lysates immunoprecipitated with caveolin-1 specific IgG1 ((mo)CAV1), or
irrelevant anti-thyroid hormone receptor antibody (ctrl), and subjected to
SDSePAGE. Immunoblot analysis of whole cell extract (input), immunode-
pleted supernatants (ID) and immunoprecipitates (IP) was performed using
rabbit polyclonal antibodies against CAV1 ((rb)CAV1), CB1R, NAPE-PLD,
FAAH and TRPV1. Molecular weights of marker proteins are indicated on
the right. C, Colocalization of CAV1 and CB1R by confocal microscopy. The
yellow spots indicate that CAV1 and CB1R colocalize, and are present mainly
in intracellular vesicles. Membrane fractionation, immunoprecipitation, confo-
cal microscopy and dilution of specific antibodies were as described in Section
2. Reported blots and images are representative of triplicate experiments.corroborated by immunoprecipitation studies. The latter
showed that almost all CB1R co-immunoprecipitated with
CAV1 in C6 cell extracts as revealed by the complete immu-
nodepletion of CB1R in the flowthrough of the immunoprecip-
itation (Fig. 1B). Instead TRPV1, NAPE-PLD and FAAH did
not co-immunoprecipitate with CAV1 (Fig. 1B), in keeping
with previous biochemical data showing that they do not func-
tion within lipid rafts (Bari et al., 2005, 2006b). On the other
hand, the lack of commercially available antibodies specific
for DAGL or MAGL did not allow to further extend to these
proteins the co-localization studies.
Additional confocal microscopy analysis further supported
the colocalization of CB1R and CAV1 in C6 cells, demon-
strating that CB1 receptors are predominantly localized intra-
cellularly (Fig. 1C). It should be recalled that recent data in
HEK-293 cells transfected with CB1R-EGFP (enhanced green
fluorescence protein) plasmids have shown that a substantial
proportion (z85%) of receptors is indeed localized in intra-
cellular vesicles (Leterrier et al., 2004).
3.2. Trafficking of CB1R and CAV1 upon MCD treatment
CB1R has been shown to permanently and constitutively
cycle between plasma membrane and endosomes (Hsieh
et al., 1999; Leterrier et al., 2004). Therefore, we sought to as-
certain the possible role of CAV1 in this trafficking. To this
end, we examined the localization patterns of CB1R and
CAV1 in C6 cells treated with MCD, that disrupts raft integrity
in C6 cells (Bari et al., 2005) as well as in many other cell
types (Rybin et al., 2000: Kunzelmann-Marche et al., 2002;
Xiang et al., 2002). MCD caused a time-dependent recycling
of CB1R, that was superimposable on that of CAV1 (Fig. 2).
Furthermore, MCD led to a time-dependent increase of
CB1R immunoreactivity (Fig. 3), at the same dose (2.5 mM)
and in the same time range (0e30 min) that has been shown
to double the number of binding sites of the receptor, and
hence its binding efficiency (Bari et al., 2005). It seems note-
worthy that this time frame is not compatible with de novo
protein synthesis, suggesting that MCD treatment might in-
crease the accessibility of the binding sites to the anti-CB1R
antibodies. Interestingly, these antibodies have been shown
to antagonize the effect of natural or synthetic CB1R agonists
(Maccarrone et al., 2005), suggesting that indeed they react
with the binding site of the receptor.
4. Discussion
Lipid rafts are subdomains of the plasma membrane that
contain high concentrations of cholesterol and glycosphingoli-
pids, and are well-known modulators of GPCR-dependent sig-
naling and membrane trafficking in central and peripheral cells
(Gajate and Mollinedo, 2005; Rodgers et al., 2005).
We have demonstrated that, in rat C6 glioma cells, raft per-
turbation by MCD treatment enhances CB1R binding and sig-
naling (Bari et al., 2005). Shortly afterwards, independent
reports have shown that CB1R is localized within lipid rafts
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(Sarnataro et al., 2005, 2006), and in human endothelial cells
(Bari et al., 2006b). Remarkably, the different dependence of
CB1 and CB2 receptors on raft integrity was observed also
in primary cells (Bari et al., 2006b).
Here, we supplement novel information that demonstrates
that CB1R resides almost entirely in a specialized type of lipid
Fig. 3. Effect of MCD on CB1R immunoreactivity. C6 cells were treated for
the indicated periods of time with 2.5 mM MCD, and immunofluorescence
was recorded at 20 (upper panels) or at 60 (lower panels) magnification.
Cell nuclei were stained in blue with DAPI, whereas localization of CB1 re-
ceptors is shown as green spots. Reported images are representative of tripli-
cate experiments.
Fig. 2. Trafficking of CAV1 and CB1R upon MCD treatment. C6 cells were
treated for the indicated periods of time with 2.5 mM MCD, and immunoflu-
orescence was recorded at 40 magnification. Cells were double stained with
antibodies against CB1 receptors (red) and caveolin-1 (green). Reported im-
ages are representative of triplicate experiments.rafts, the caveolae. This observation suggests a strong link be-
tween CB1R and CAV1, that seems interesting because caveo-
lae play a role in neurodegenerative diseases, like Parkinson’s
disease, Alzheimer’s disease and dementia with Lewy’s bodies
(Hashimoto et al., 2003), as well as in other neurological
abnormalities (Trushina et al., 2006). Notably, also endocan-
nabinoids have been shown to interfere with these processes
through CB1R-dependent mechanisms (Van der Stelt and Di
Marzo, 2005; Maccarrone et al., 2007).
Caveolae represent a subset of lipid rafts, characterized by
high caveolin content and formation of 50e100 nm flask-
shaped membrane invaginations (Pike, 2003). Caveolins are
a family of scaffolding proteins critical for the organization
of preassembled signaling complexes within the plasma mem-
brane, and are known to regulate the activity of several G pro-
teins (Okamoto et al., 1998; Simons and Toomre, 2000;
Simons and Ehehalt, 2002; Pike, 2003). The CAV1 isoform
has been identified in C6 cells (Silva et al., 1999), as well as
in many other rat and human glioma cells (Cameron et al.,
2002). Our present finding that CB1R co-localizes with
CAV1 in this type of cells (Fig. 1AeC) suggests that at least
part of the enhancement of CB1R signaling observed upon
lipid raft disruption by MCD (Bari et al., 2005) may involve
CAV1. In support of this hypothesis, we show that MCD
causes a CB1R trafficking that is superimposable on that of
CAV1 (Fig. 2), and that it enhances the accessibility of recep-
tor binding sites to specific anti-CB1R antibodies (Fig. 3). Of
particular relevance seems the fact that activation of CB1R
protects neurons, astrocytes and several peripheral cells
against apoptosis (Guzman, 2003; Maccarrone, 2006). In
line with this, lipid rafts disruption has been shown to block
apoptosis induced in vitro by AEA in glioma cells (Sarker
and Maruyama, 2003) and hepatocytes (Biswas et al., 2003),
as a consequence of CB1R activation (Bari et al., 2005). On
the other hand activation of CB1R can also promote apoptosis
in vitro, for instance in glioma cells (Galve-Roperh et al.,
2000), and in rat cortical astrocytes and human astrocytoma
cells (Sa`nchez et al., 2001). Generally speaking, it seems
that activation of CB1 receptors modulates the balance among
different signals (like FAN, ERK, JNK and p38 MAPK, PI3K/
PKB), that in turn impact the cell choice between proliferation
and death, driving it towards apoptotic or anti-apoptotic
pathways (reviewed by Maccarrone, 2006). At any rate,
CB1R-dependent pro-apoptotic signals may contribute to the
pro-apoptotic activity of CAV1. In fact this substance, befitting
its role as a multi-tasking molecule, has been shown to sensi-
tize cells towards apoptosis, by regulating cell cycle progres-
sion and by activating pro-apoptotic signals like bcl2, p53
and p21 (Shajahan et al., 2007). Since several human glioblas-
toma tumors possess CAV1 (Cameron et al., 2002), and deple-
tion of cholesterol in lipid rafts has been shown to inhibit
apoptosis induced by anti-tumor drugs (Gajate and Mollinedo,
2001), this investigation raises the suggestive although still
speculative idea that perturbation of lipid rafts, by modulating
CB1R- and CAV1-dependent signaling, may be involved in
finely tuning cell survival and death within the central nervous
system. This concept might be exploited for the treatment of
49M. Bari et al. / Neuropharmacology 54 (2008) 45e50endocannabinoid-related diseases that are CB1R-dependent,
such as brain injury (Mechoulam et al., 2002) and oxidative
stress (Carracedo et al., 2004), cancer (Guzman, 2003), and
neurodegenerative disorders (Piomelli, 2003; Maccarrone
et al., 2007).
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